The opposite prognostic effect of TP53 mutation in oligodendroglioma compared to astrocytoma represents the critical molecular and mechanistic differences between the two histological sub-types and emphasises the need to analyse these sub-types as separate cohorts in transcriptomic and survival studies. The gene discussed is TP53; the disease is astrocytoma (excluding glioblastoma).